Mineralys Therapeutics, Inc.(MLYS)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
MLYS Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Mineralys Therapeutics, Inc. (MLYS), a Healthcare sector company. MLYS is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Top institutional holders of MLYS by reported 13-F value include Catalys Pacific, RA CAPITAL MANAGEMENT, L.P., BlackRock, based on the most recent SEC filings. MLYS trades on the Nasdaq exchange and files with the SEC under CIK 1933414. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MLYS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Mineralys Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-241.1M
D/E Ratio
Q2 2026
0.00
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
+13.0% YoYOperating Income
+11.3% YoYEPS (Diluted)
+37.4% YoYTotal Assets
+221.4% YoYOp. Cash Flow
+14.4% YoYFree Cash Flow
+14.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Income | $-154.7M +13.0% | $-177.8M -147.3% | $-71.9M -141.3% | $-29.8M | — |
| Operating Income | $-170.6M +11.3% | $-192.4M -127.3% | $-84.7M -168.9% | $-31.5M | — |
| EPS (Diluted) | $-2.29 +37.4% | $-3.66 -83.9% | $-1.99 +65.5% | $-5.77 | — |
| Total Assets | $661.8M +221.4% | $205.9M -18.2% | $251.6M +119.9% | $114.4M | — |
| Operating Cash Flow | $-142.4M +14.4% | $-166.3M -104.9% | $-81.2M -177.8% | $-29.2M | — |
| Free Cash Flow | $-142.4M +14.4% | $-166.4M -105.0% | $-81.2M | — | — |
Get alerted when MLYS's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Mineralys Therapeutics, Inc. including:
Top Institutional Holders of MLYS
Catalys Pacific, LLC
$213.2M7,903,838 shRA CAPITAL MANAGEMENT, L.P.
$207.6M7,692,750 shBlackRock, Inc.
$158.8M5,887,038 shSamsara BioCapital, LLC
$158.4M5,871,018 shFMR LLC
$121.7M4,511,689 shSTATE STREET CORP
$111.7M4,141,636 shDEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$106.8M3,958,000 shVANGUARD CAPITAL MANAGEMENT LLC
$74.4M2,756,770 shLaurion Capital Management LP
$67.6M2,506,152 shPRICE T ROWE ASSOCIATES INC /MD/
$61.0M2,262,476 sh
| Fund | Value | Shares |
|---|---|---|
| Catalys Pacific, LLC | $213.2M | 7,903,838 |
| RA CAPITAL MANAGEMENT, L.P. | $207.6M | 7,692,750 |
| BlackRock, Inc. | $158.8M | 5,887,038 |
| Samsara BioCapital, LLC | $158.4M | 5,871,018 |
| FMR LLC | $121.7M | 4,511,689 |
| STATE STREET CORP | $111.7M | 4,141,636 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | $106.8M | 3,958,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $74.4M | 2,756,770 |
| Laurion Capital Management LP | $67.6M | 2,506,152 |
| PRICE T ROWE ASSOCIATES INC /MD/ | $61.0M | 2,262,476 |
More Healthcare Companies
View all Healthcare →Put MLYS on your watchlist
Track score changes the day Mineralys Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MLYS a good stock to buy?
13F Pro's AI-powered analysis of Mineralys Therapeutics, Inc. (MLYS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MLYS are available on the MLYS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MLYS is classified as a mid company.
Which hedge funds own MLYS?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MLYS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Mineralys Therapeutics, Inc.'s investment landscape.